Bruxism, Myalgia, Quality of Life
Conditions
Keywords
myalgia, Botulinum toxin, bruxism, Dry needling, manual therapy
Brief summary
Eighty individuals (44 female, 36 male), which were randomly divided into 4 groups of 20 patients each, due to the treatment type: Botulinum toxin (BTX); Dry needling (DN); Pharmacological therapy (PT) and Manual therapy (MT). All treatments were carried out by the same maxillofacial surgeon. An informed consent form was obtained from all participants.
Detailed description
The study aimed to assess and compare the effectiveness of 4 different methods in the management bruxism: Botulinum toxin (BTX-A), dry needling (DN), pharmacological therapy (PT), and manual therapy (MT). 80 bruxist patients (44 female, 36 male) were randomly divided into 4 groups of 20 patients each. Botulinum toxin, dry needling, pharmacological therapy and manual therapy were carried out by the same maxillofacial surgeon in all patients. The following measurements were recorded by another investigator in each group, at baseline (before treatment) and at post-treatment intervals of 2nd, 4th, and 12th weeks; Visual Analogue Scale (VAS) for pain, maximum painless mouth opening (mm), Oral Health Impact Profile14 (OHIP-14).
Interventions
DRUGBotulinum toxin
Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
PROCEDUREDry needling
Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
DRUGMyorel
Metacarbamol (380mg), paracetamol (300mg)
PROCEDUREManual therapy
Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
Sponsors
Saglik Bilimleri Universitesi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Participants were informed only about the type of treatment they received. The results were measured and recorded by another researcher other than the operator.
Intervention model description
Group 1: Botulinum toxin (BTX-A) injection (n=20) Group 2: Dry needling (DN) (n=20) Group 3: Pharmacological therapy (PT) (n=20) Group 4: Manual therapy (MT) (n=20)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult patients aged 18 to 65 years with complete dentition, * Patients classified as American Society of Anesthesiologists (ASA) physical status ASA I or ASA II * Patients experiencing moderate to severe pain in the masticatory muscles related to bruxism, * Patients who had not previously been treated for bruxism * Patients who were diagnosed with bruxism were excluded from the study.
Exclusion criteria
* Presence of temporomandibular joint disorder * Known allergy to botulinum toxin * Pregnancy * Presence of neuromuscular disease * Chronic use of muscle relaxant medication within the last 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain in at rest and at chewing | 12 weeks | Average pain was measured by a scale, named Visual analogue scale. |
| MMO | 12 weeks | Maximum painless mouth opening (in millimeters) was measured by a special ruler. |
| OHRQoL questionnaire | 12 weeks | Oral-health-related quality of life |
Countries
Turkey (Türkiye)
Outcome results
None listed